Biopharmaceutical Research Consortium Structure and Governance

CQDM operates through its representative bodies: the Board of Directors and its committees, officers, members and other representatives.

Board of Directors

The Board of Directors and its five sub-committees are largely responsible for the governance of the biopharmaceutical research consortium. Members of the Board meet four times per year and oversee the sound management of the biopharmaceutical research consortium. They ensure that financial matters are dealt with carefully and independently, in compliance with the selection criteria of each funding program maintained by CQDM.

Members of the Board of Directors represent all stakeholders of the biopharmaceutical research consortium and draw on their extensive experience to help CQDM maximize the impact of funded projects and reach its objectives.

Chairman

Richard Fajzel
Chief Executive Officer,
Exactis Innovation

Observers

Martin Houle
Director, Industrial Partnerships,
Quebec Ministry of Economy, Science and Innovation (MESI)

Monika Michalska
Senior Program Manager,
Networks of Centres of Excellence

Secretary

François Painchaud 
Lawyer, Partner,
ROBIC, LLP

Members

Jennifer Chan
Vice President, Policy and Communications,
Merck Canada

Diane Gosselin
President and Chief Executive Officer,
CQDM

Raphael Hofstein
President and Chief Executive Officer,
MaRS Innovation

Ken Pastor
General Partner,
CTI Capital

Louise Proulx
Chief Development Officer,
Therillia Development Company

Jorge Puente
Co-Founder and Managing Partner,
Pleasanton Pharma Ventures

Rémi Quirion
Chief Scientist officer of Québec,
Fonds de recherche du Québec

Uwe Schoenbeck
Senior VP & Chief Scientific Officer, External R&D Innovation,
Pfizer worldwide R&D

Ali Tehrani
Co-founder, President and CEO,
Zymeworks

Patrick J. Wier
Senior Vice President,
In Vitro/In Vivo Translation Platform, GSK

Executive Committee

The Executive Committee meets regularly to settle specific aspects of the biopharmaceutical research consortium’s business activities.

Chairman

Richard Fajzel
Chief Executive Officer,
Exactis Innovation

Members

Jennifer Chan
Vice President, Policy and Communications,
Merck Canada

Diane Gosselin
President and Chief Executive Officer,
CQDM

Raphael Hofstein
President and Chief Executive Officer,
MaRS Innovation

Audit Committee

The Audit Committee is a sub-committee of the Board that meets at least twice per year to review the financial statements and receive notification of any errors or misstatements contained in financial statements from the external auditors.

Chairman

Ken Pastor
General Partner,
CTI Capital

Membre

Domenic De Luca
Vice President, Finance and Administration,
Gladius Pharmaceuticals

Richard Fajzel
Chief Executive Officerl,
Exactis Innovation

Corporate Governance and Nominating Committee

The Corporate Governance and Nominating Committee ensures that the best resources and members are supporting the structure and governance of the biopharmaceutical research consortium.
The Committee oversees the recruitment, resignation and replacement process of new Board members. Its ultimate goal is to help CQDM focus on executing its strategy, while leveraging the experience of the Board.

Chairman

Richard Fajzel
Chief Executive Officer,
Exactis Innovation

Members

Jennifer Chan
Vice President, Policy and Communications,
Merck Canada

Raphael Hofstein
President and Chief Executive Officer,
MaRS Innovation

Diane Gosselin
President and Chief Executive Officer,
CQDM

Scientific Advisory Board

The Scientific Advisory Board was created by the Board of Directors and is comprised of experienced and independent scientists. The members examine all external scientific reviews obtained by CQDM, ensure that projects targeted for funding meet all selection criteria and present their recommendations to the Board of Directors. The Scientific Advisory Board is the reason why CQDM can testify that it maintains a stringent selection process that maximizes positive R&D impacts for its members.

Chairman

Daniel Hétu
Managing Director,
Lumira Capital

Observers

Monika Michalska
Senior Program Manager,
Networks of Centres of Excellence

Catherine Richard
Advisor, Industrial Partnerships,
Quebec Ministry of Economy, Science and Innovation (MESI)

Members

Karen Akinsanya
Chief Biomedical Scientist,
Schrödinger

André Darveau
Vice Rector, Administration,
Université Laval

Diane Gosselin
President and Chief Executive Officer,
CQDM

Reid Jason Leonard
Senior Vice President, Corporate Development,
Potenza Therapeutics

Mark Lim
Program Officer, Diagnostics,
Integrated Development and Global Health,
Gates Foundation